

**HIF-1 α siRNA Enhances the Efficacy of Erlotinib in Non-Small Cell Lung
Cancer: A Novel Strategy to Reverse Hypoxia-Induced Drug Resistance**

Drugs in R&D

Haojie Jiang^{a,b,c,†}, Shunhui Cai^{a,b,c,†}, Xiaojun Zhang^{a,b,c}, Shijie Chen^{a,b,c}, Chunyan Yue

^{a,b,c*}, Wu Yin^{a,b,c*}, Yiqiao Hu^{a,b,c*}

^a *State Key Laboratory of Pharmaceutical Biotechnology, Medical School & School of
Life Sciences, Nanjing University, Nanjing 210093, China*

^b *Jiangsu Key Laboratory for Nano Technology, Nanjing University, Nanjing, China*

^c *Institute of Drug R&D, School of Life Science, Nanjing University, Nanjing, China*

[†] These authors contributed equally to this work.

* Corresponding authors

E-mail addresses: yuechunyan@nju.edu.cn (C.Y. Yue), wyin@nju.edu.cn (W. Yin),

huyiqiao@nju.edu.cn (Y.Q. Hu).




Fig. S1. (a) Quantification of HIF-1 α protein expression following knockdown with candidate siRNA sequences using a HIF-1 α ELISA kit. (b) RT-qPCR analysis of HIF-1 α mRNA expression after knockdown with candidate siRNA sequences.




Fig. S2. (a–d) Flow cytometric analysis of changes in reactive oxygen species (ROS) levels in H1975 cells after HIF-1 α siRNA treatment under normoxic and hypoxic conditions. (a) ROS expression in H1975 cells treated with non-specific siRNA under normoxia. (b) ROS expression in H1975 cells treated with HIF-1 α siRNA under normoxia. (c) ROS expression in H1975 cells treated with non-specific siRNA under hypoxia. (d) ROS expression in H1975 cells treated with HIF-1 α siRNA under hypoxia.

Gene	Sequence	
	sense (5'-3')	antisense (5'-3')
siRNA-HIF1 α -419	GUUGCCACUUCCACAUAUAUTT	AUUAUGUGGAAGUGGCAACTT
siRNA-HIF1 α -874	CAGGCCACAUUCACGUAUATT	UAUACGUGAAUGUGGCCUGTT
siRNA-HIF1 α -2180	CCGUAUGGAAGACAUAUAATT	UUUAAUGUCUCCAUAACGGTT
siRNA-HIF1 α -2367	GUCGCUUUGAGUCAAGAATT	UUCUUUGACUCAAGCGACTT

Table S1. HIF-1 α candidate siRNA sequence